Combined IL6 and CCR2 blockade potentiates antitumor activity of NK cells in HPV-negative head and neck cancer

Fan Yang,Chenyang Yuan,Fanghui Chen,Zhaohui S. Qin,Nicole C. Schmitt,Gregory B. Lesinski,Nabil F. Saba,Yong Teng

DOI: https://doi.org/10.1186/s13046-024-03002-1

IF: 12.658

2024-03-13

Journal of Experimental & Clinical Cancer Research

Abstract:While T cell-activating immunotherapies against recurrent head and neck squamous cell carcinoma (HNSCC) have shown impressive results in clinical trials, they are often ineffective in the majority of patients. NK cells are potential targets for immunotherapeutic intervention; however, the setback in monalizumab-based therapy in HNSCC highlights the need for an alternative treatment to enhance their antitumor activity.

oncology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to enhance the anti - tumor activity of natural killer (NK) cells in human papillomavirus (HPV) - negative head and neck squamous cell carcinoma (HNSCC) by blocking the IL6 and CCR2 signaling pathways.

### Background
- **HNSCC** is a cancer originating from the mucosal epithelial cells in the head and neck, including cancers in multiple parts such as the oral cavity, pharynx, hypopharynx and larynx.
- **HPV infection** has an important impact on the occurrence and development of HNSCC. HPV - positive HNSCC patients usually have a better prognosis, while HPV - negative HNSCC patients have a poorer prognosis.
- **Immunotherapy** such as immune checkpoint inhibitors (ICIs) shows good efficacy in HPV - positive HNSCC, but has limited effect in HPV - negative HNSCC.
- **NK cells** are an important type of immune cells that can recognize and attack tumor cells, but their role in HPV - negative HNSCC is limited.

### Research Objectives
- **Identify key molecular changes**: Identify key molecular changes in NK cells through single - cell RNA sequencing (scRNA - seq) and TCGA HNSCC data sets.
- **Verify bioinformatics findings**: Use representative HPV - positive (+) and HPV - negative (−) HNSCC cell lines and orthotopic mouse models to verify bioinformatics findings.
- **Evaluate the effect of combination therapy**: Explore whether simultaneously blocking the IL6 and CCR2 signaling pathways can enhance the anti - tumor activity of NK cells, especially in HPV - negative HNSCC.

### Main Findings
- **IL6/IL6R and CCL2/CCR2 signaling pathways**: In HPV - negative HNSCC, these pathways have a more significant impact on NK cells escaping immune attack.
- **IL6 blockade**: In the orthotopic mouse model, using an IL6 - neutralizing antibody to inhibit the IL6 signal can inhibit the growth of HPV - negative tumors and increase the infiltration and proliferation of CD161+ NK cells in the tumor.
- **Combination therapy**: The combined use of the CCR2 chemokine receptor antagonist RS504393 and IL6 blockade can more significantly enhance the anti - tumor effect, manifested as more activated NK cells in the tumor.

### Conclusion
- **Dual - pathway blockade**: Simultaneously blocking the IL6 and CCR2 signaling pathways can effectively enhance the anti - tumor activity of NK cells in HPV - negative HNSCC, providing a new strategy for treating this type of cancer.

### Keywords
- Head and neck cancer
- NK cells
- IL6 and CCR2
- Single - cell RNA sequencing
- HPV
- Tumor microenvironment
- Dual blockade

Through these studies, the authors hope to provide a new immunotherapy strategy for HPV - negative HNSCC patients to improve their survival rate and quality of life.